Pancreatic Cancer Research

ResearcherPeking University First HospitalActive in the last 2 years

Feng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9403-4337; OpenAlex author ID A5100431330. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, p… Co-author DOI 10.1186/s12943-025-02437-0↗
  2. Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagi… Co-author DOI 10.1002/ijc.31211↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yun‐Xin Lu · 1 shared paper, 2025 · strength 0.20
  2. Dongsheng Zhang · 1 shared paper, 2025 · strength 0.20
  3. Feng‐Hua Wang · 1 shared paper, 2025 · strength 0.20
  4. Ming-Ming He · 1 shared paper, 2025 · strength 0.20
  5. Xiaodong Tian · 1 shared paper, 2018 · strength 0.09
  6. Zhengkui Zhang · 1 shared paper, 2018 · strength 0.09
  7. Yongsu Ma · 1 shared paper, 2018 · strength 0.09
  8. Yinmo Yang · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.